Helpful resources for providers,
patients, and caregivers

Roland (4 years old), a real VILTEPSO patient and compensated spokesperson, and his father

Access personalized support and customized resources

Our experienced, knowledgeable team at NS Support Patient Access Solutions is dedicated to assisting patients, their caregivers, and healthcare professionals throughout the treatment journey. We’re committed to being there for you every step of the way.

Visit NS Support

For Healthcare Professionals

  • Enroll patients in NS Support Patient Access Solutions using our Patient Start Form
  • Rapid benefits investigation and verification
  • Highly responsive reimbursement support and follow-up calls
  • Insights about infusion site options for your patients
  • Streamlined product acquisition options

For Patients and Caregivers

  • Individualized, caring support and resources throughout the patient journey
  • Co-pay Assistance Program—eligible patients may qualify for savings on their deductible, co-pay, and coinsurance for their medication costs for VILTEPSO*
  • Financial Assistance Program—provides medication free of charge to patients who meet eligibility requirements

*Program covers the cost of the medication only and does not cover the costs to administer the infusion. See full Eligibility Requirements & Terms and Conditions.

VILTEPSO Resources

For Healthcare Providers

Healthcare Provider Overview Brochure

Summarizes the clinical evidence of the efficacy and safety of VILTEPSO and other product features

Dosing & Administration Guide

Provides information on how to prescribe, dose, and administer VILTEPSO as infusion therapy

For Patients and Caregivers

Patient Overview Brochure

Explains the features of VILTEPSO in treating Duchenne, including efficacy and safety

Doctor Discussion Guide

Offers helpful questions to ask your doctor when speaking about VILTEPSO

Getting Started & Infusion Overview Guide

Contains essential information about the weekly IV infusion process, and helps answer any questions you may have

Gray arrow used to indicate Important Safety Information section. EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
  • You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.

For more information about VILTEPSO, see full Prescribing Information.